Company Encyclopedia
View More
name
Inhibrx Biosciences
INBX.US
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
1.946 T
INBX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking365/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-144.07%E
    • Profit Margin-11077.57%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-19.26%E
    • Net Profit YoY-109.45%E
    • Total Assets YoY-20.26%E
    • Net Assets YoY-79.36%E
  • Cash ScoreD
    • Cash Flow Margin-0.90%D
    • OCF YoY-19.26%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio79.25%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Inhibrx Biosciences Reports Promising Q3 2025 Results

    Inhibrx Biosciences reported promising Q3 2025 results, highlighting progress in clinical trials, especially for ozekibart (INBRX-109) in treating chondrosarcoma. Financially, the company saw a decrease in cash to $153.1 million and reduced R&D expenses to $28.5 million. Despite a net loss of $35.3 million, this was an improvement from the previous year. Inhibrx plans to submit a biologics license application for ozekibart in 2026, with positive interim data for colorectal cancer and Ewing sarcoma programs.

    Tip Ranks·
    US
    INBX
    +5.36%
    Tip Ranks·
    US
    INBX
    +5.36%

    Inhibrx Biosciences (NASDAQ:INBX) Issues Earnings Results

    Inhibrx Biosciences (NASDAQ:INBX) announced its quarterly earnings, reporting a loss of $2.28 per share, beating the consensus estimate of $2.94 loss. The stock rose 6.0% to $79.13. The company has a market cap of $1.15 billion and a debt-to-equity ratio of 1.45. Analysts have mixed ratings on the stock. Major shareholder Global Investors Lp Viking sold 350,000 shares. Institutional investors own 82.46% of the company's stock.

    Market Beat·
    US
    INBX
    +5.36%
    Market Beat·
    US
    INBX
    +5.36%

    Inhibrx Biosciences posts Q3 net loss of $35.3 million

    Inhibrx Biosciences Inc. reported a Q3 2025 net loss of $35.3 million, an improvement from $43.9 million in Q3 2024. R&D expenses decreased to $28.5 million. Cash reserves fell to $153.1 million. Positive trial results for ozekibart were announced, with plans for FDA submission in Q2 2026. The report was AI-generated by PUBT.

    Reuters·
    US
    INBX
    +5.36%
    Reuters·
    US
    INBX
    +5.36%

    Inhibrx Biosciences Unveils Positive Phase 2 Results for DR5 Agonist Ozekibart in Chondrosarcoma

    Inhibrx Biosciences Inc. announced positive Phase 2 results for its DR5 agonist, ozekibart (INBRX-109), in chondrosarcoma. The company will present clinical data at several conferences in November 2025, including the 21st Annual Industry/Academia Precision Oncology & Radmed Symposium and the CTOS 2025 Annual Meeting. The presentations will cover results from the Phase 2 ChonDRAgon study and preclinical data on glioblastoma models. Further details will be available on the company's investor website after each event.

    Reuters·
    US
    INBX
    +5.36%
    Reuters·
    US
    INBX
    +5.36%

    Understanding the Market | TRANSCENTA-B is currently up over 4%, ozekibart will submit a U.S. indication marketing application before mid-next year

    TRANSCENTA-B once surged nearly 10% during trading, and as of the time of publication, it rose 4.75% to HKD 3.09, with a trading volume of HKD 4.006 million. In terms of news, TRANSCENTA announced that its partner Inhibrx Biosciences, Inc. recently reported positive primary results from the registrational clinical study of the tetravalent death receptor 5 (DR5) agonistic antibody ozekibart, which evaluated the efficacy of ozekibart monotherapy compared to placebo in patients with advanced or metastatic, unresectable sarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the sarcoma indication of this product to U.S. regulators by the end of June 2026. TRANSCENTA currently holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan

    Zhitong·
    HK
    06628
    +5.06%
    Zhitong·
    HK
    06628
    +5.06%
    © 2025 Longbridge｜Disclaimer